Exploring the Impact of Treatment Switching on Overall Survival from the PROfound Study in Homologous Recombination Repair (HRR)-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC).
Loading...
Embargo End Date
ICR Authors
Authors
Evans, R
Hawkins, N
Dequen-O'Byrne, P
McCrea, C
Muston, D
Gresty, C
Ghate, SR
Fan, L
Hettle, R
Abrams, KR
de Bono, J
Hussain, M
Agarwal, N
Hawkins, N
Dequen-O'Byrne, P
McCrea, C
Muston, D
Gresty, C
Ghate, SR
Fan, L
Hettle, R
Abrams, KR
de Bono, J
Hussain, M
Agarwal, N
Document Type
Journal Article
Date
2021-09-03
Date Accepted
2021-08-20
Abstract
BACKGROUND: In oncology trials, treatment switching from the comparator to the experimental regimen is often allowed but may lead to underestimating overall survival (OS) of an experimental therapy. OBJECTIVE: This study evaluates the impact of treatment switching from control to olaparib on OS using the final survival data from the PROfound study and compares validated adjustment methods to estimate the magnitude of OS benefit with olaparib. PATIENTS AND METHODS: The primary population from PROfound (Cohort A) was included, alongside two populations approved for treatment with olaparib by the European Medicines Agency and US Food and Drug Administration: BRCAm and Cohort A+B (excluding the PPP2R2A gene). Five methods were explored to adjust for switching: excluding or censoring patients in the control arm who receive subsequent olaparib, Rank Preserving Structural Failure Time Model (RPSFTM), Inverse Probability of Censoring Weights, and Two-Stage Estimation. RESULTS: The RPSFTM was considered the most appropriate approach for PROfound as the results were robust to sensitivity analysis testing of the common treatment effect assumption. For Cohort A, the final OS hazard ratio reduced from 0.69 (95% CI 0.5-0.97) to between 0.42 (0.18-0.90) and 0.52 (0.31-1.00) for olaparib versus control, depending on the RPSFTM selected. Median OS reduced from 14.7 months to between 11.73 and 12.63 months for control. CONCLUSIONS: The magnitude of the statistically significant (P < 0.05) survival benefit of olaparib versus control observed in Cohort A of PROfound is likely to be underestimated if adjustment for treatment switching from control to olaparib is not conducted. The RPSFTM was considered the most plausible method, although further development and validation of robust methods to estimate the magnitude of impact of treatment switching is needed.
Citation
Targeted Oncology, 2021, 16 (5), pp. 613 - 623
Source Title
Targeted Oncology
Publisher
SPRINGER
ISSN
1776-2596
eISSN
1776-260X
1776-260X
1776-260X
Collections
Research Team
PrCa Targeted Therapy